Background: To determine the efficacy of high-dose antioxidants in the acute stage of central serous\r\nchorioretinopathy (CSC).\r\nMethods: This was a randomized placebo-controlled study. The patients with acute CSC (onset within 6 weeks)\r\nwere randomized to receive either high-dose antioxidant tablets (study group A) or placebo tablets (control group\r\nB) for 3 months or until the complete resolution of subretinal fluid. After 3 months, additional treatment with laser\r\nor photodynamic therapy (PDT) was considered if any fluorescein leakage persisted. The outcomes measured were\r\nthe changes in visual acuity (VA) and central macular thickness (CMT), the number of patients with subretinal fluid\r\nat each follow-up time, the number of patients with fluorescein leakage at the end of the 3rd month and patients\r\nwho received additional treatments.\r\nResults: Fifty-one of 58 patients (88%) completed the follow-up criteria. The baseline demographic data were\r\ncomparable in both groups. At the end of the 3rd month, the VA and CMT showed no statistical difference\r\nbetween the groups but the patients in group A has less fluorescein leakage and additional treatments than in\r\ngroup B (p = 0.027 and 0.03).\r\nConclusion: The high-dose antioxidants for acute CSC did not show any benefits in VA and CMT. However, the\r\ndrugs might decrease the chance for fluorescein leakage and additional treatments at the end of the 3rd month.
Loading....